Advertisement

Topics

High Dose Somatostatin Analogues in Neuroendocrine Tumors

2014-07-23 21:12:35 | BioPortfolio

Summary

Octreotide (OCT) is a somatostatin analogue (SSA) available in a long-acting formulation, conventionally administered every 28 days at the maximum dose of 30 mg. Together with lanreotide, it is considered the therapy of choice in the control of endocrine syndromes associated with neuroendocrine tumors (NET)s. A complete or partial clinical response to SSA therapy is generally achieved in at least 50% of the patients with neuroendocrine syndrome. Many studies reported a clinical response in 70-90% of functioning NETs. In about 36-50% of the patients with progressive advanced well differentiated NET (WDNET), a stabilization of disease occurs after treatment with subcutaneous OCT. By developing long-acting slow-release SSA formulation, long-acting OCT (LAR), lanreotide-SR, lanreotide-Autogel, the patient's compliance to SSA therapy was improved and escape from treatment, which was common with the subcutaneous formulation, was avoided. However, rate of objective response was not significantly improved as compared to short-acting SSA. On the other hand, it has to be remarked that long-acting SSA are being used in NET patients at doses correspondent to the low doses of short-acting formulation. The higher commercially available doses of LAR is 30 mg, which is assumed to be comparable to 300 µg of short-acting OCT in the therapy of acromegaly.

Only one study was designed to investigate the use of high-dose LAR (160 mg every 28 days). In this study, objective and hormonal responses in patients with progressive metastatic ileal NET non-responder to standard doses, was significantly elevated. However, this compound has never been commercialized and, of consequence, this first preliminary observation has not been confirmed by further studies.

No systematic studies were performed with the commercially available long-acting SSA used in high-dose treatments. In patients with progressive locally advanced or metastatic NET, increase of the dose or reduction of the interval between injections is a relatively common "empirical" clinical practice, but no studies have been performed to evaluate safety and efficacy of this treatment schedule.

Description

The patient population will include the patients with a histologically documented diagnosis of WDNET, defined according to the last WHO Classification criteria for NET of gastro-entero-pancreatic, bronchial, thymic or other origin; and showing tumor progression under a standard dose treatment with LAR (30 mg every 28 days) for at least 6 months. Progressive disease will be defined as increased tumor size according to RECIST definitions.

Study Design

Allocation: Non-Randomized, Control: Uncontrolled, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Respiratory Tract Neoplasms

Intervention

Octreotide-LAR

Location

University Federico II of Naples
Naples
Italy
80131

Status

Completed

Source

Federico II University

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-07-23T21:12:35-0400

Clinical Trials [1299 Associated Clinical Trials listed on BioPortfolio]

A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms

The aim of this study is to investigate the clinical value of [18F]aluminum fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-octreotide(18F-AlF-NOTA-octreotide ) positron emission...

A Study of Octreotide Depot vs Saline Control in Pediatric Hypothalamic Obesity Patients

The extension protocol is designed to allow those patients randomized to placebo in the core portion of the protocol to receive a 6 month treatment of open label octreotide and allow those...

RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness

RSV infections can develop into serious, life threatening conditions among immunocompromised patients. The objective of this study (ADMA 001) is to evaluate the safety and efficacy of RI-...

Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly

Octreotide capsule is a novel, orally-administered formulation of the commercially-available injectable drug octreotide. In a recent phase 3 trial, oral octreotide capsules demonstrated ma...

Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly

Epidemiological data indicate that patients with active acromegaly have reduced life expectancy because of cardiovascular (60%) and respiratory diseases (25%) mainly (1-10). A post-treatme...

PubMed Articles [4873 Associated PubMed Articles listed on BioPortfolio]

Octreotide Use in Neonates: A Case Series.

Octreotide is a somatostatin analogue and has been used off-label for a variety of conditions. There are no specific guidelines for the use of octreotide in neonates and its safety and efficacy have n...

Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge.

Gastroenteropancreatic neuroendocrine tumors (NETs) are a relatively rare group of heterogeneous neoplasms. The most significant advance in therapy of NETs has been the advent of the somatostatin anal...

Reductions in otitis and other respiratory tract infections following childhood pneumococcal vaccination.

Streptococcus pneumoniae commonly causes respiratory tract infections including acute otitis media and pneumonia. In this study, we evaluated the impact of general infant pneumococcal vaccination, int...

Case Report: Intraductal Papillary Mucinous Neoplasms of the Biliary Tract.

The present case report describes intraductal papillary mucinous neoplasms of the biliary tract (IPMN-BT), a rare neoplasm of the biliary tract that is described as the biliary counterpart of intraduc...

Post-consultation illness trajectories in children with acute cough and respiratory tract infection: prospective cohort study.

Little is known about respiratory tract infection (RTI) severity in children following consultation.

Medical and Biotech [MESH] Definitions

New abnormal growth of tissue in the RESPIRATORY SYSTEM.

An abnormal passage communicating between any component of the respiratory tract or between any part of the respiratory system and surrounding organs.

That part of the RESPIRATORY TRACT or the air within the respiratory tract that does not exchange OXYGEN and CARBON DIOXIDE with pulmonary capillary blood.

Granulomatous disorders affecting one or more sites in the respiratory tract.

Respiratory system manifestations of diseases of the respiratory tract or of other organs.

More From BioPortfolio on "High Dose Somatostatin Analogues in Neuroendocrine Tumors"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Endocrine Disorders
Endocrine disorders are grouped into two categories: hormone imbalance - when a gland produces too much or too little of an endocrine hormone development of lesions (such as nodules or tumors) in the endocrine system, which may or may not affect...


Searches Linking to this Trial